drug · small molecule

deupirfenidone

Phase 2updated 5mo ago

by Celea Therapeutics🔗 ChEMBL

Phase 2

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.

indications

Pulmonary Fibrosis

all catalysts(0)

nothing on the calendar yet

Trials studying deupirfenidone

phase3Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)recruitingn=1,100
phase1PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjectscompletedn=116
phase2LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=240

News(2)

A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
biopharma_dive · 2mo ago
Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5M
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
fiercebiotech · 9mo ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 6h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

deupirfenidone

Phase 2updated 5mo ago

by Celea Therapeutics🔗 ChEMBL

Phase 2

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.

indications

Pulmonary Fibrosis

all catalysts(0)

nothing on the calendar yet

Trials studying deupirfenidone

phase3Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)recruitingn=1,100
phase1PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjectscompletedn=116
phase2LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=240

News(2)

A PureTech startup banks $180M for a new IPF drug
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
biopharma_dive · 2mo ago
Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5M
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
fiercebiotech · 9mo ago

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 6h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

deupirfenidone

indications

all catalysts(0)

Trials studying deupirfenidone

News(2)

Report a data issue

comments(0)

deupirfenidone

indications

all catalysts(0)

Trials studying deupirfenidone

News(2)

Report a data issue

comments(0)